Clinical settingPatients with CUP treated with platinum chemotherapy (plus taxanes in 66% of cases) at a single institution between 1997 and 2005
Participants and Country93 patients. Most had lymph node metastasis (78%). Japan.
Study designRetrospective case series.
Target conditionResponse to chemotherapy, assessed using WHO criteria for treatment response. Overall survival
Testsβ-hCG (threshold >10 ng/ml), AFP (threshold> 0.5 mIU/ml), CEA (threshold> 5.0 ng/ml), CA 19-9 (threshold> 37 U/ml).
Follow upNot reported. Survival was analysed up to 3 years after treatment, at the time of analysis 64/93 patients had died

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.